An Early Phase 1 clinical trial (NCT05204290) evaluating pembrolizumab in combination with decompressive spine radiosurgery for epidural spinal tumors was officially terminated on 2026-06-29. The study enrolled only one participant before its termination, and no outcome measurements or analyses were reported.
Background
This trial investigated pembrolizumab (also known as Keytruda) in participants with high-grade epidural disease of the spine and cancer. The research aimed to understand the effects of combining pembrolizumab with radiosurgery for this condition.
Trial design
This was an Early Phase 1 study (NCT05204290) titled "Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab". The trial was designed to assess the effects, both beneficial and adverse, of pembrolizumab and radiosurgery in participants diagnosed with epidural spinal tumors and cancer. The study enrolled a total of one participant before its status was changed to TERMINATED.
What this means
The early termination of this Early Phase 1 trial after enrolling only one participant signifies that the study did not proceed to a stage where comprehensive efficacy or safety data could be collected or reported. Consequently, no conclusions can be drawn regarding the investigational combination of pembrolizumab and radiosurgery for epidural spinal tumors based on the data from this particular trial.
Source
The trial status and details were posted on 2026-06-29 on ClinicalTrials.gov, an official database of clinical studies. The full information is available on clinicaltrials.gov under the identifier NCT05204290.